Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Objective: To examine the rate and time to relapse for remitters and responders to ketamine in treatment-resistant depression (TRD). Methods: Subjects with TRD were randomized to a single infusion of one of several doses of intravenous ketamine, or midazolam. Using Kaplan-Meier survival function, the current report examines the rate and time to relapse, defined as MADRS ≥ 22, over a period of 30 days, in subjects who achieved remission (MADRS ≤ 10) or response (≥ 50% reduction in MADRS) on day three post-infusion of intravenous ketamine 0.1, 0.5, or 1.0 mg/kg. Results: Of the 60 randomized participants who received a single ketamine (0.1, 0.5, or 1.0 mg/kg) infusion, 19 (34%) met criteria for remission and 27 (48%) for response, on day 3 post-infusion. A numerical dose-response relationship was observed, with remitters/responders on ketamine 1.0 mg/kg having the lowest relapse rate, followed by ketamine 0.5 mg/kg and 0.1 mg/kg, respectively (% of remitters who relapsed by day 14: 38% with 1.0 mg/kg, 50% with 0.5 mg/kg, 100% with 0.1 mg/kg; % of responders who relapsed by day 14: 30% with 1.0 mg/kg, 50% with 0.5 mg/kg, 80% with 0.1 mg/kg). Limitations: The sample size was small. No MADRS measurements at day one post-infusion. The study was not powered to assess differences in relapse prevention between different doses of ketamine. Conclusion: Time to relapse after successful treatment with a single infusion of ketamine appears to follow a dose-response relationship, where higher dosage leads to increased time to relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541 · cited 1×
“In the past decades, a number of pharmacological treatments for major depression have proven successful, in a substantial proportion of patients, to significantly reduce depressive symptomatology, albeit through a common pathway, namely the modulation of the monoaminergic system (Cipriani et al., 2018).”
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 14×
“An NIMH-funded network, Rapidly-Acting Treatments for Treatment-Resistant Depression (RAPID) (“Rapidly-Acting Treatments for Treatment-Resistant Depression (RAPID). https://www.nimh.nih.gov/research-priorities/research-initiatives/rapidly-acting-treatmentsfor-treatment-resistant-depression-rapid.shtml,”), recently con…”
BackgroundSelf-citationDaly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718 · cited 1×
“While this is the only study comparing response and remission rates of various doses of intravenous ketamine over the course of several weeks, our results appear similar to those recently reported with repeatdose (twice-weekly) administration of intranasal esketamine (28mg, 56mg, or 84 mg) (Daly et al., 2018).”
ResultA Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576
Self-citationSingh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525
Self-citationFava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0256-5 · Cited by 433 · cited 9×
“…of intravenous ketamine in patients with unipolar treatment-resistant depression (TRD), and demonstrated that responses to ketamine at doses of 0.1mg/kg, 0.5 mg/kg and 1.0 mg/kg (but not 0.2mg/kg) were found to be superior to midazolam (active placebo) at day one post-infusion (Fava et al., 2018).”
BackgroundMethodResultInfluentialSelf-citationAntidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review
Molero, P., Ramos-Quiroga, J. A., Martin-Santos, R., Calvo-Sánchez, E., Gutiérrez-Rojas, L., & Meana, J. J. (2018) · CNS Drugs · doi:10.1007/s40263-018-0519-3 · Cited by 280 · cited 1×
“Since then, there have been several published randomized controlled trials (RCT) confirming the acute and robust antidepressant effect of a single infusion of ketamine (Ionescu & Papakostas, 2016, 2017; Molero et al., 2018).”
BackgroundLiu, R.-J., Fuchikami, M., Dwyer, J. M., Lepack, A. E., Duman, R. S., & Aghajanian, G. K. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.128 · Cited by 256 · cited 2×
“medial prefrontal cortex (mPFC) pyramidal neurons of rats, which are associated with sustained antidepressant-like responses persisting for up to 1 week in the forced-swim test (Li et al., 2010; Liu et al., 2013).”
BackgroundA Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders
Wilkinson, S. T., Toprak, M., Turner, M. S., Levine, S. P., Katz, R. B., & Sanacora, G. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17020239 · Cited by 125 · cited 1×
“fewer clinic visits) and reducing its cost (clinicians currently employ two to three infusions per week (Wilkinson et al., 2017)).”
BackgroundSelf-citationGaspersz, R., Lamers, F., Kent, J. M., Beekman, A. T. F., Smit, J. H., van Hemert, A. M., Schoevers, R. A., & Penninx, B. W. J. H. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10221 · Cited by 88 · cited 1×
“TRD is associated with a reduced quality of life, social and occupational impairment, high rates of medico-psychiatric comorbidities, higher likelihood of prior suicide attempt, and substantially increased resource utilization (Gaspersz et al., 2017; Greden, 2001; Kautzky et al., 2017; Nelsen & Dunner, 1995; Russell e…”
Background
Cited by
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
“Repeated-dose intravenous racemic ketamine has demonstrated efficacy for up to 2–3 weeks (20, 147).”
BackgroundResultInfluentialSelf-citationGukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211073759 · Cited by 425
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., et al. (2022) · CNS Drugs · doi:10.1007/s40263-021-00877-y · Cited by 127
“In recognition of the inadequacy of conventional first-line antidepressants and the unmet needs of individuals with TRD, along with the recent US Food and Drug Administration and European Medicines Agency approval of esketamine [8], * Roger S. McIntyre roger.mcintyre@uhn.ca Extended author information available on the…”
BackgroundInfluentialKetamine and psychotherapy for the treatment of psychiatric disorders: Systematic review
Kew, B. M., Porter, R. J., Douglas, K. M., Glue, P., Mentzel, C. L., & Beaglehole, B. (2023) · BJPsych Open · doi:10.1192/bjo.2023.53 · Cited by 69
Conley, A. A., Norwood, A. E. Q., Hatvany, T. C., Griffith, J. D., & Barber, K. E. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05825-8 · Cited by 39
Metadata
- Authors
- Salloum, N. C., Fava, M., Hock, R. S., Freeman, M. P., Flynn, M., Hoeppner, B., Cusin, C., Iosifescu, D. V., Trivedi, M. H., Sanacora, G., Mathew, S. J., Debattista, C., Ionescu, D. F., & Papakostas, G. I.
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 260
- Pages
- 131-139
- ISSN
- 0165-0327 (ISSN-L)
- OpenAlex
- W2971894339
- Cited by
- 34
- References
- 10
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. https://app.cochat.ai/papers/10.1016/j.jad.2019.09.017
- The paper
- Salloum, N. C., Fava, M., Hock, R. S., Freeman, M. P., Flynn, M., Hoeppner, B., Cusin, C., Iosifescu, D. V., Trivedi, M. H., Sanacora, G., Mathew, S. J., Debattista, C., Ionescu, D. F., & Papakostas, G. I. (2020). Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2019.09.017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.